REG - Dr. Martens PLC - Total Voting Rights

Dr MartensAnnouncement

30/01/2026 11:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260130:nRSd1223Ra&default-theme=true

RNS Number : 1223R  Dr. Martens PLC  30 January 2026

Dr. Martens plc (the "Company")

 

Total Voting Rights

 

The following information is released in accordance with the FCA's Disclosure
Guidance and Transparency Rule 5.6.1.

 

As at the date of this disclosure, the Company's issued ordinary share capital
consists of 967,319,559 ordinary shares of GBP 0.01 each, each carrying one
voting right. The Company does not hold any shares in Treasury. Therefore, the
total number of shares with voting rights in the Company is 967,319,559.

 

The above figure (967,319,559) can be used by shareholders as the denominator
for the calculations by which to determine if they are required to notify
their interest in, or a change to their interest in, the Company under the
FCA's Disclosure Guidance and Transparency Rules.

 

For further information please contact:

 

Paul Rolling

Head of Secretariat

Dr. Martens plc

+44 7584 243562

 

About Dr. Martens

Dr. Martens is an iconic British footwear brand founded in Northamptonshire,
England. Its first silhouette, the 1460 boot - named after the date it was
produced - rolled off the production line on 1st April 1960. Originally chosen
by workers for their air-cushioned comfort and durability, "Docs" or "DM's"
were later adopted by musicians and subcultural pioneers who took them from
the street to the global stage.

Over six decades later, Dr. Martens operates in more than 60 countries and
employs around 3,700 people. The company continues to honour the brand's
heritage through its 'Made in England' footwear, manufactured at its original
Northamptonshire factory, while meeting global demand from multiple
high-quality production sites across Asia. All our products are made with an
unwavering commitment to craft, combined with innovative techniques.

A brand built to put a bounce in the step of those who stand out from the
crowd, Dr. Martens is available through Direct-to-Consumer (Retail and
Ecommerce) and Wholesale channels. The brand's collections range from its
Original silhouettes - The Icons such as the 1460 boot, 1461 shoe, 2976
Chelsea boot, and Adrian loafer - to modern franchises like the Zebzag, Buzz,
and Lowell. The lineup also includes an extensive range of sandals, a
dedicated Kids collection, and a curated selection of bags, small leather
goods, and accessories.

Every Dr. Martens collection reflects craftsmanship, heritage, timeless style,
comfort, and versatility. Having transcended generations, the brand stays as
relevant today as it was at its inception. Its signature yellow welt
stitching, grooved sole edges, and scripted "With Bouncing Soles" heel loops
remain iconic symbols recognised around the world.

Dr. Martens plc (DOCS.L) is listed on the main market of the London Stock
Exchange and is a constituent of the FTSE 250 index.

For more information, visit www.drmartens.com or www.drmartensplc.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRFLFLLLSIIVIR



            Copyright 2019 Regulatory News Service, all rights reserved